Loading...
•
Jun 30
Quest Diagnostics Q2 2025 Earnings Report
Quest Diagnostics reported strong financial results for the second quarter of 2025, with significant increases in revenue, EPS, and cash provided by operations, leading to raised full-year guidance.
Key Takeaways
Quest Diagnostics delivered a robust second quarter in 2025, with total revenues reaching $2.76 billion, marking a 15.2% increase year-over-year. Diluted EPS grew by 21.7% to $2.47, and adjusted diluted EPS increased by 11.5% to $2.62. The company also saw a substantial 51.5% rise in cash provided by operations, reaching $544 million for the quarter. This strong performance led Quest Diagnostics to raise its full-year 2025 guidance for both reported and adjusted diluted EPS.
Second quarter revenues increased by 15.2% to $2.76 billion, driven by organic growth and acquisitions.
Reported diluted EPS rose by 21.7% to $2.47, and adjusted diluted EPS increased by 11.5% to $2.62.
Cash provided by operations for the quarter was $544 million, a 51.5% increase compared to the prior year.
The company raised its full-year 2025 guidance for both reported and adjusted diluted EPS, reflecting confidence in continued performance.
Quest Diagnostics
Quest Diagnostics
Quest Diagnostics Revenue by Segment
Revenue by Segment
Diagnostic Information Services Revenue
CapyFin.com Forward Guidance
Quest Diagnostics has raised its full-year 2025 guidance, anticipating net revenues between $10.80 billion and $10.92 billion, and reported diluted EPS between $8.60 and $8.80. Adjusted diluted EPS is expected to be between $9.63 and $9.83, with cash provided by operations around $1.55 billion.
Positive Outlook
- Raised full-year net revenue guidance to $10.80 billion - $10.92 billion (previously $10.70 billion - $10.85 billion).
- Increased full-year reported diluted EPS guidance to $8.60 - $8.80 (previously $8.62 - $8.87).
- Adjusted diluted EPS guidance raised to $9.63 - $9.83 (previously $9.55 - $9.80).
- Cash provided by operations expected to be approximately $1.55 billion (previously $1.5 billion).
- Net revenues increase expected to be between 9.4% and 10.6%.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the provided text.
- The range for reported diluted EPS guidance has a slightly lower floor compared to prior guidance ($8.60 vs $8.62).
- Future impacts to earnings related to special items may occur throughout 2025.
- The amount of excess tax benefits (ETB) is dependent upon employee stock option exercises and stock price, which are difficult to predict.
- The company's forward-looking statements involve risks and uncertainties that could cause actual results to be materially different.